Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study

Table 5 Logistic regression analysis of factors associated with AKI in patients who received CMS and CMS/NAs.

		Univariate analysis			Multivariate analysis^b
Variables	No. AKI/total (%)	O.R.	95% C.I.	P -value	O.R.	95% C.I.	P -value
Age, years ^a
<55	23/71 (32)	1.00
≥55	34/76 (45)	1.68	0.86-3.31	0.13
Sex
Male	39/95 (41)	1.00
Female	18/52 (34)	0.76	0.37-1.53	0.44
SAPS II ^a
<43	20/73 (27)	1.00
≥43	37/74 (50)	2.65	1.33-5.27	<0.01	2.26	1.07-4.79	0.03
Septic shock at Infection onset
No	20/89 (22)	1.00
Yes	37/58 (64)	6.1	2.92-12.62	<0.01	5.64	2.66-11.94	<0.01
Treatment with CMS
CMS with NAs	26/57 (45)	1.00
CMS alone	31/90 (34)	0.62	0.31-1.23	0.17
Cumulative CMS dose ^a,c
<93.999.975 (IU)	33/73 (45)	1.00
≥93.999.975 (IU)	24/74 (32)	0.58	0.29-1.13	0.11	0.61	0.29-1.29	0.19
Duration of CMS therapy ^a
<11 days	30/72 (42)	1.00
≥11 days	27/35 (36)	0.78	0.4-1.53	0.48

The variables included in the final predictive model were selected with a stepwise procedure: age and treatment with CMS were not included in the final model.
^a age, SAPS II, duration of CMS therapy, and cumulative CMS dose were dichotomized around median values. ^b The ROC curve analysis was used to assess the goodness of the final logistic regression model (AUC ± SE = 0.76 ± 0.04 with 95% CI 0.7 to 0.8; Chi-square statistics P <0.001). ^c Includes loading dose of 4,000,000 IU.
AKI, acute kidney injury; AUC, area under the curve; CI, confidence interval; CMS, colistin methanesulfate; IBW, ideal body weight; IU, international unit; NAs, nephrotoxic antibiotics (aminoglycosides, glycopeptides); ROC, receiver operating characteristic; SAPS II, Simplified Acute Physiology Score II (calculated 24 h after ICU admission).

ISSN: 1364-8535